Efficacy and Safety Study of ABT-436 in Major Depressive Disorder
Public ClinicalTrials.gov record NCT01741142. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of ABT-436 in Major Depressive Disorder
Study identification
- NCT ID
- NCT01741142
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Enrollment
- 19 participants
Conditions and interventions
Conditions
Interventions
- ABT-436 Drug
- Escitalopram Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2011
- Primary completion
- Sep 30, 2013
- Completion
- Jul 31, 2015
- Last update posted
- Oct 7, 2013
2012 – 2015
United States locations
- U.S. sites
- 18
- U.S. states
- 12
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site Reference ID/Investigator# 85593 | Little Rock | Arkansas | 72211 | — |
| Site Reference ID/Investigator# 87228 | Garden Grove | California | 92845 | — |
| Site Reference ID/Investigator# 87214 | National City | California | 91950 | — |
| Site Reference ID/Investigator# 87220 | Oakland | California | 94612 | — |
| Site Reference ID/Investigator# 87215 | Bradenton | Florida | 34201 | — |
| Site Reference ID/Investigator# 87225 | South Miami | Florida | 33143 | — |
| Site Reference ID/Investigator# 85594 | Atlanta | Georgia | 30328 | — |
| Site Reference ID/Investigator# 85580 | Marlton | New Jersey | 08053 | — |
| Site Reference ID/Investigator# 87227 | Brooklyn | New York | 11235 | — |
| Site Reference ID/Investigator# 87223 | New York | New York | 10128 | — |
| Site Reference ID/Investigator# 87217 | Dayton | Ohio | 45417 | — |
| Site Reference ID/Investigator# 87226 | Portland | Oregon | 97210 | — |
| Site Reference ID/Investigator# 87221 | Philadelphia | Pennsylvania | 19139 | — |
| Site Reference ID/Investigator# 87219 | Austin | Texas | 78731 | — |
| Site Reference ID/Investigator# 87216 | Dallas | Texas | 75231 | — |
| Site Reference ID/Investigator# 87933 | Houston | Texas | 77008 | — |
| Site Reference ID/Investigator# 88874 | Salt Lake City | Utah | 84106 | — |
| Site Reference ID/Investigator# 88876 | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01741142, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 7, 2013 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01741142 live on ClinicalTrials.gov.